Stem Cell Research & Therapy, Год журнала: 2024, Номер 15(1)
Опубликована: Авг. 13, 2024
Hemorrhagic stroke is a devastating cerebrovascular event with high rate of early mortality and long-term disability. The therapeutic potential mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) for neurological conditions, such as intracerebral hemorrhage (ICH), has garnered considerable interest, though their mechanisms action remain poorly understood.
Язык: Английский
Fluids and Barriers of the CNS, Год журнала: 2022, Номер 19(1)
Опубликована: Июль 25, 2022
Abstract Extracellular vesicles (EVs) are particles naturally released from cells that delimited by a lipid bilayer and unable to replicate. How the EVs cross Blood–Brain barrier (BBB) in bidirectional manner between bloodstream brain parenchyma remains poorly understood. Most vitro models have evaluated this event relied on monolayer transwell or microfluidic organ-on-a-chip techniques do not account for combined effect of all cellular layers constitute BBB at different sites Central Nervous System. There has been direct transcytosis visualization through mammals vivo, evidence comes vivo experiments zebrafish. Literature is scarce topic, describing mechanisms motion inconsistent. This review will focus methodologies used evaluate transcytosis, how overcome fundamental structure, discuss potential methodological approaches future analyses clarify these issues. Understanding be essential their use as vehicles pharmacology therapeutics.
Язык: Английский
Процитировано
151
Theranostics, Год журнала: 2022, Номер 12(11), С. 4879 - 4903
Опубликована: Янв. 1, 2022
In recent decades, extracellular vesicles (EVs), as bioactive cell-secreted nanoparticles which are involved in various physiological and pathological processes including cell proliferation, immune regulation, angiogenesis tissue repair, have emerged one of the most attractive nanotherapeutics for regenerative medicine. Herein we provide a systematic review latest progress EVs applications. Firstly, will briefly introduce biogenesis, function isolation technology EVs. Then, underlying therapeutic mechanisms native unmodified engineering strategies modified entities be discussed. Subsequently, main focus placed on repair regeneration applications organs brain, heart, bone cartilage, liver kidney, well skin. More importantly, current clinical trials medicine also highlighted. Finally, future challenges insightful perspectives currently developed EV-based biomedicine short, opened new horizons biologists, chemists, nanoscientists, pharmacists, clinicians, making possible powerful tools therapies
Язык: Английский
Процитировано
74
Theranostics, Год журнала: 2023, Номер 13(12), С. 4138 - 4165
Опубликована: Янв. 1, 2023
Neurodegenerative diseases are characterized by the progressive loss of neurons and intricate interactions between different cell types within affected regions.Reliable biomarkers that can accurately reflect disease activity, diagnose, monitor progression neurodegenerative crucial for development effective therapies.However, identifying suitable has been challenging due to heterogeneous nature these diseases, affecting specific subsets in brain regions.One promising approach promoting regeneration recovery involves transplantation mesenchymal stem cells (MSCs).MSCs have demonstrated ability modulate immune system, promote neurite outgrowth, stimulate angiogenesis, repair damaged tissues, partially through release their extracellular vesicles (EVs).MSC-derived EVs retain some therapeutic characteristics parent MSCs, including regulate facilitate tissue repair.This review aims explore potential MSC-derived as an emerging strategy highlighting role modulating neuronal recovery.By elucidating mechanisms which exert effects, we advance our understanding leverage novel treatment approaches field diseases.
Язык: Английский
Процитировано
66
Journal of Controlled Release, Год журнала: 2023, Номер 356, С. 493 - 506
Опубликована: Март 15, 2023
Diseases of the central nervous system (CNS) are challenging to treat, mainly due blood-brain barrier (BBB), which restricts drugs in circulation from entering target regions brain. To address this issue extracellular vesicles (EVs) have gained increasing scientific interest as carriers able cross BBB with multiplex cargos. EVs secreted by virtually every cell, and their escorted biomolecules part an intercellular information gateway between cells within brain other organs. Scientists undertaken efforts safeguard inherent features therapeutic delivery vehicles, such protecting transferring functional cargo, well loading them small molecules, proteins, oligonucleotides targeting specific cell types for treatment CNS diseases. Here, we review current emerging approaches that engineer EV surface cargo improve responses We summarize existing applications engineered a platform diseases, some been evaluated clinically.
Язык: Английский
Процитировано
41
Bioactive Materials, Год журнала: 2025, Номер 48, С. 149 - 170
Опубликована: Фев. 18, 2025
Язык: Английский
Процитировано
1
Advanced Healthcare Materials, Год журнала: 2022, Номер 11(21)
Опубликована: Сен. 2, 2022
Extracellular vesicles (EVs), acting as an important ingredient of intercellular communication through paracrine actions, have gained tremendous attention in the field tissue engineering (TE). Moreover, these nanosized extracellular particles (30-140 nm) can be incorporated into biomaterials according to different principles facilitate signal delivery various regenerative processes directly or indirectly. Bioactive carrier will extend retention time and realize controlled release EVs, which further enhance their therapeutic efficiency regeneration. Herein, basic biological characteristics EVs are first introduced, then outstanding performance exerting direct impacts on target cells regeneration well indirect effects promoting angiogenesis regulating immune environment, due specific functional components (nucleic acid, protein, lipid, etc.), is emphasized. Furthermore, design ideas for suitable EV-loaded also demonstrated. In end, this review highlights engineered strategies, aim at solving problems related natural such highly heterogeneous functions, inadequate targeting capabilities, insufficient yield scalability, etc., thus pertinence clinical potential EV-based approaches TE.
Язык: Английский
Процитировано
36
Molecular Therapy, Год журнала: 2023, Номер 31(5), С. 1275 - 1292
Опубликована: Апрель 6, 2023
Machado-Joseph disease (MJD)/spinocerebellar ataxia type 3 (SCA3) is the most common autosomal dominantly inherited worldwide. It caused by an over-repetition of trinucleotide CAG within ATXN3 gene, which confers toxic properties to ataxin-3 (ATXN3) species. RNA interference technology has shown promising therapeutic outcomes but still lacks a non-invasive delivery method brain. Extracellular vesicles (EVs) emerged as vehicles due their capacity deliver small nucleic acids, such microRNAs (miRNAs). miRNAs were found be enriched into EVs specific signal motifs designated ExoMotifs. In this study, we aimed at investigating whether ExoMotifs would promote packaging artificial used treat MJD/SCA3. We that miRNA-based silencing sequences, associated with ExoMotif GGAG and ribonucleoprotein A2B1 (hnRNPA2B1), retained silence mutant (mutATXN3) 3-fold EVs. Bioengineered containing neuronal targeting peptide RVG on surface significantly decreased mutATXN3 mRNA in primary cerebellar neurons from MJD YAC 84.2 novel dual-luciferase mouse model upon daily intranasal administration. Altogether, these findings indicate bioengineered carrying sequences are vehicle for brain therapy.
Язык: Английский
Процитировано
22
Nanoscale, Год журнала: 2023, Номер 15(26), С. 10904 - 10938
Опубликована: Янв. 1, 2023
This review summarizes recent advances in extracellular vesicle-based carriers for glioblastoma diagnosis and therapy, points out the current challenges perspectives.
Язык: Английский
Процитировано
17
Nano Today, Год журнала: 2024, Номер 55, С. 102169 - 102169
Опубликована: Янв. 26, 2024
Язык: Английский
Процитировано
7
CNS & Neurological Disorders - Drug Targets, Год журнала: 2024, Номер 23(11), С. 1357 - 1370
Опубликована: Фев. 14, 2024
Extracellular vesicles or exosomes, often known as EVs, have acquired significant attention in the investigations of traumatic brain injury (TBI) and a distinct advantage actively researching fundamental mechanisms underlying various clinical symptoms diagnosing wide range cases. The mesenchymal stem cells (MSCs) can produce release which offer therapeutic benefits. Exosomes are tiny membranous produced by cellular entities originating from endosomes. Several studies reported that administering MSC-derived exosomes through intravenous infusions improves neurological recovery promotes neuroplasticity rats with damage. advantages be attributed to microRNAs (miRNAs), small non-coding regulatory RNAs significantly impact regulation posttranscriptional genes. Exosome-based therapies, do not involve cells, lately gained interest potential breakthrough enhancing accelerating for injuries neurodegenerative diseases. This article explores benefits drawbacks exosome treatment while emphasizing latest advancements this field significance.
Язык: Английский
Процитировано
7